Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea
<h4>Objectives</h4> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness in coronavirus disease (COVID-19) patients with breakthrough infections has not been established in South Korea. To address this, we assessed the impact of vaccination on symptom occurr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431655/?tool=EBI |
| _version_ | 1797736854794010624 |
|---|---|
| author | Jieun Jang Hyopin Jeong Bong-Hwa Kim Sura An Hye-Ryun Yang Sunjoo Kim |
| author_facet | Jieun Jang Hyopin Jeong Bong-Hwa Kim Sura An Hye-Ryun Yang Sunjoo Kim |
| author_sort | Jieun Jang |
| collection | DOAJ |
| description | <h4>Objectives</h4> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness in coronavirus disease (COVID-19) patients with breakthrough infections has not been established in South Korea. To address this, we assessed the impact of vaccination on symptom occurrence and viral load. <h4>Methods</h4> We performed a retrospective cohort study of 9,030 COVID-19 patients enrolled between February and November 2021. The impact of vaccination on the incidence of symptoms and viral load as indicated by cycle threshold (Ct) values of RdRp and E genes was evaluated using relative risks (RRs) and 95% confidence intervals (95% CIs). <h4>Results</h4> Compared with unvaccinated patients, fully vaccinated patients were associated with a reduced symptom onset of cough, sputum, and myalgia in COVID-19 patients (RR (95% CI) = 0.86 (0.75–0.99) for cough; RR (95% CI) = 0.74 (0.56–0.98) for sputum; RR (95% CI) = 0.65 (0.53–0.79) for myalgia, respectively). Additionally, lower risk of high viral load, Ct value of RdRp gene <15 or Ct value of E gene <15, was observed especially in fully vaccinated patients younger than 40 years ((RR (95% CI) = 0.69 (0.49–0.96) for RdRp gene; (RR (95% CI) = 0.71 (0.53–0.95) for E gene). <h4>Conclusion</h4> SARS-CoV-2 vaccination was associated with a reduced risk of COVID-19 symptoms as well as decreased viral load, especially in patients younger than 40 years. |
| first_indexed | 2024-03-12T13:19:56Z |
| format | Article |
| id | doaj.art-f42ef006c3694da8b0504805d43d9c11 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-12T13:19:56Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f42ef006c3694da8b0504805d43d9c112023-08-26T05:31:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01188Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South KoreaJieun JangHyopin JeongBong-Hwa KimSura AnHye-Ryun YangSunjoo Kim<h4>Objectives</h4> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness in coronavirus disease (COVID-19) patients with breakthrough infections has not been established in South Korea. To address this, we assessed the impact of vaccination on symptom occurrence and viral load. <h4>Methods</h4> We performed a retrospective cohort study of 9,030 COVID-19 patients enrolled between February and November 2021. The impact of vaccination on the incidence of symptoms and viral load as indicated by cycle threshold (Ct) values of RdRp and E genes was evaluated using relative risks (RRs) and 95% confidence intervals (95% CIs). <h4>Results</h4> Compared with unvaccinated patients, fully vaccinated patients were associated with a reduced symptom onset of cough, sputum, and myalgia in COVID-19 patients (RR (95% CI) = 0.86 (0.75–0.99) for cough; RR (95% CI) = 0.74 (0.56–0.98) for sputum; RR (95% CI) = 0.65 (0.53–0.79) for myalgia, respectively). Additionally, lower risk of high viral load, Ct value of RdRp gene <15 or Ct value of E gene <15, was observed especially in fully vaccinated patients younger than 40 years ((RR (95% CI) = 0.69 (0.49–0.96) for RdRp gene; (RR (95% CI) = 0.71 (0.53–0.95) for E gene). <h4>Conclusion</h4> SARS-CoV-2 vaccination was associated with a reduced risk of COVID-19 symptoms as well as decreased viral load, especially in patients younger than 40 years.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431655/?tool=EBI |
| spellingShingle | Jieun Jang Hyopin Jeong Bong-Hwa Kim Sura An Hye-Ryun Yang Sunjoo Kim Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea PLoS ONE |
| title | Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea |
| title_full | Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea |
| title_fullStr | Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea |
| title_full_unstemmed | Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea |
| title_short | Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea |
| title_sort | vaccine effectiveness in symptom and viral load mitigation in covid 19 breakthrough infections in south korea |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431655/?tool=EBI |
| work_keys_str_mv | AT jieunjang vaccineeffectivenessinsymptomandviralloadmitigationincovid19breakthroughinfectionsinsouthkorea AT hyopinjeong vaccineeffectivenessinsymptomandviralloadmitigationincovid19breakthroughinfectionsinsouthkorea AT bonghwakim vaccineeffectivenessinsymptomandviralloadmitigationincovid19breakthroughinfectionsinsouthkorea AT suraan vaccineeffectivenessinsymptomandviralloadmitigationincovid19breakthroughinfectionsinsouthkorea AT hyeryunyang vaccineeffectivenessinsymptomandviralloadmitigationincovid19breakthroughinfectionsinsouthkorea AT sunjookim vaccineeffectivenessinsymptomandviralloadmitigationincovid19breakthroughinfectionsinsouthkorea |